Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concernLaura Vangeel, Dirk Jochmans|Antiviral Research|2022Cited by 430
Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against CoronavirusesAndreas Luttens, Jens Carlsson, Eldar Abdurakhmanov et al.|Journal of the American Chemical Society|2022Cited by 244